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Abstract
Background: Some low molecular weight heparins (LMWHs) prolong survival of cancer patients and inhibit experimental
metastasis. The underlying mechanisms are still not clear but it has been suggested that LMWHs (at least in part) limit
metastasis by preventing cancer cell-induced destruction of the endothelial glycocalyx.
Methodology/Principal Findings: To prove or refute this hypothesis, we determined the net effects of the endothelial
glycocalyx in cancer cell extravasation and we assessed the anti-metastatic effect of a clinically used LMWH in the presence
and absence of an intact endothelial glycocalyx. We show that both exogenous enzymatic degradation as well as
endogenous genetic modification of the endothelial glycocalyx decreased pulmonary tumor formation in a murine
experimental metastasis model. Moreover, LMWH administration significantly reduced the number of pulmonary tumor foci
and thus experimental metastasis both in the presence or absence of an intact endothelial glycocalyx.
Conclusions: In summary, this paper shows that the net effect of the endothelial glycocalyx enhances experimental
metastasis and that a LMWH does not limit experimental metastasis by a process involving the endothelial glycocalyx.
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Introduction
In experimental animal models and clinical studies it has been
well established that some low molecular weight heparins
(LMWH) inhibit experimental metastasis and prolong survival
[1,2]. Although the underlying mechanisms are only partially
understood, it has been suggested that the endothelial glycocalyx
may play an important role in the life prolonging effects of
LMWH in patients.
The endothelial glycocalyx is a negatively charged, organized
network of membranous glycoproteins, proteoglycans and glycos-
aminoglycans that affects several biological processes with
potential importance for cancer cell extravasation. First, the
endothelial glycocalyx is essential for vascular barrier function. Its
disruption by pro-inflammatory cytokines, including tumor
necrosis factor (TNF-a) and glycocalyx-degrading enzymes such
as heparanase and hyaluronidase, leads to increased vascular
permeability [3–5]. Second, the glycocalyx has anticoagulant
properties and thrombin generation is reduced by the glycocalyx
because it stores various natural anticoagulant factors such as
antithrombin, protein C and tissue factor pathway inhibitor [6].
Consequently, disruption of the endothelial glycocalyx instantly
results in thrombin generation and platelet adhesion [7]. Third,
through its diversity in biochemical make-up, the endothelial
glycocalyx both prevents and facilitates cell adhesion to the
endothelium. The size of the glycocalyx (predominantly its
heparan sulphate proteoglycan and hyaluronate composition)
exceeds the size of the adhesion molecules (syndecan-1, L- and P-
selectin), thereby masking these proteins and preventing adhesion
of among others leukocytes [8]. On the other hand, when
glycocalyx bound components such as hyaluronic acid are released
they may serve as ligands for the CD44 receptor expressed on
many cells (including cancer cells). The glycocalyx thus plays an
important role in cell adhesion to the vessel wall [9,10]. Fourth,
the glycocalyx binds growth factors and extracellular matrix
components via its proteoglycan syndecan-1. Moreover, syndecan-
1 modulates fibroblast growth factor-2 (FGF-2) and vascular
endothelial growth factor (VEGF) activity [11]. The glycocalyx is a
sink of growth factors that in general are anti-apoptotic and of
VEGF that can increase endothelial permeability [12]. Overall,
the endothelial glycocalyx may thus be an important player in
several biological processes with potential relevance for cancer cell
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metastatic effects of the endothelial glycocalyx in vivo remains to be
elucidated however.
Interestingly, cancer cells produce enzymes that are known to
degrade the endothelial glycocalyx, such as heparanase and
hyaluronidase [12–16]. These enzymes consequently influence
vascular endothelial barrier integrity, adhesive properties of the
endothelial lining, cytokine production and can liberate heparan
sulfate-bound growth factors thereby inducing cancer cell extrav-
asation. As heparin, LMWHs and heparin derivatives can abolish
the activity or binding of heparanase [17,18] and hyaluronidase
[19] by competingwithheparansulphates and hyaluronan [20–22],
it has been hypothesized that LMWHs (at least in part) limit cancer
progression by restoring cancer cell-induced glycocalyx damage
thereby limiting cancer cell extravasation [23].
In the current manuscript, we aimed to assess whether the effect
of a LMWH on experimental metastasis depends on restoration of
the endothelial glycocalyx. To this end, we first determined the net
effect of the endothelial glycocalyx in experimental metastasis.
Next, we assessed the effect of a LMWH in the presence or
absence of an intact endothelial glycocalyx to determine the
contribution of the glycocalyx to the effect of this LMWH on the
reduction of experimental metastasis.
Results and Discussion
To assess the net effect of the endothelial glycocalyx on
experimental metastasis, wild type mice were treated with
hyaluronidase in order to remove hyaluronan and, in part,
heparan sulphates from the endothelial glycocalyx. As it has
previously been shown that one hour after hyaluronidase
treatment vascular leakage is evident [4], B16F10 melanoma cells
were injected intravenously 1h after intravenous hyaluronidase or
saline administration. Experimental metastases in the lung were
examined 14 days later. As shown in Figure 1, the number of
pulmonary tumor foci was significantly reduced by approximately
30% after hyaluronidase treatment as compared to the saline
injected control group. Enzymatic degradation of the glycocalyx
(at least of its hyaluronan component) thus limits experimental
metastasis suggesting that the net effect of the glycocalyx is pro-
metastatic. These data imply that hyaluronidase-induced endo-
thelial barrier disruption and consequent increased vascular
permeability that would promote cancer cell extravasation is
counteracted by the loss of specific adhesion molecules and/or
growth factors from the glycocalyx. However, it should be realized
that hyaluronidase treatment may not only destroy the endothelial
glycocalyx but may also trigger the immune system which would
reduce the number of cancer cells in the circulation [24,25].
Furthermore, hyaluronidase increases circulating levels of hyalur-
onan oligomers which are known to limit cancer progression [10].
In addition, one could argue that systemic hyaluronidase
treatment may also target the glycocalyx of cancer cells and this
might be particularly relevant because impairment of the
glycocalyx makes the cancer cell vulnerable to the immune system
[26]. However, circulating hyaluronidase levels at the moment of
cancer cell inoculation are rather low due to the short half-life of
hyaluronidase (i.e. 2.7 minutes in rat plasma [27], resulting in a
circulating level of below 0.0001 U) suggesting that the observed
effect is not dependent on destruction of the cancer cell glycocalyx.
To confirm the pro-metastatic effect of the glycocalyx and to
exclude ‘‘side effects’’ like acute immunological responses [24,25]
and/or increased hyaluronan oligomers of hyaluronidase treatment
that may also be responsible for the observed reduction in cancer cell
extravasation, we assessed the effect of a genetically impaired
glycocalyx on cancer cell extravasation. To this end, syndecan-1
deficient mice were subjected to the experimental metastasis model.
Lack of this endothelial glycocalyx proteoglycan disturbs the structure
of the glycocalyx by reducing the amount of heparan sulphate
moieties. As proteoglycans bidirectionally influence their signaling
pathways, it might be expected that the reduced content of heparan
sulphate moieties is accompanied by a reduction in hyaluronan
content. As shown in Figure 2, when injected intravenously with
B16F10 melanoma cells these syndecan-1 deficient mice showed a 3-
foldreduced number of pulmonary tumor foci compared to wildtype
mice. These data show that genetic disruption of heparan sulphate
moieties of the glycocalyx is anti-metastatic as well.
Asalreadyindicated,theglycocalyxisconsidered asanintegrated
and balanced carbohydrate layer in which both hyaluronan and
heparan sulfate chains are key structural components. Importantly,
our data show that targeting either hyaluronan (enzymatically by
hyaluronidase treatment) or the heparan sulphate chains (genetic
ablation of syndecan-1) of the glycocalyx leads to reduced
experimental metastasis. As these two different interventions have
a similar effect on experimental metastasis, our data imply that
barrier protective-properties of the glycocalyx are less essential for
metastasis than its functions in cancer cell adhesion or growth factor
storage [28]. Future experiments are needed however to fully
appreciate the role of specific components of the glycocalyx on
metastasis and to elucidate the underlying mechanisms.
As mentioned before, some LMWHs protect against cancer
progression in experimental animal models and clinical trails,
including the B16F10 melanoma model of experimental metastasis.
As suggested previously, these LMWHs may inhibit metastasis
through competitive binding of heparanase or hyaluronidase
thereby protectingthe vascular endothelium and its barrier function
from disruption caused by these enzymes. To assess whether the
inhibitory effect of the administration of a LMWH on cancer
progressionaredependentonitsprotectiveeffectsontheglycocalyx,
we compared the effect of enoxaparin administration on experi-
mental metastasis in syndecan-1 deficient and wild type mice. As
shown in Figure 2, enoxaparin injected intravenously at 30 min
prior, and 6 and 12 h after cancer cell inoculation decreased the
number of pulmonary tumor foci in wild type mice almost
Figure 1. Effect of hyaluronidase on the number of B16F10
pulmonary tumor foci. C57Bl/6 mice were treated intravenously with
100U hyaluronidase 1h prior to the administration of 3.5610
5 B16F10
melanoma cells into the lateral tail vein. Mice were sacrificed 14 days after
cancer cell injection and the number of tumor foci at the surface of the
lungs was determined. Error bars represent means 6SEM (n=8); *, p,0.05.
doi:10.1371/journal.pone.0011200.g001
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reduced pulmonary tumor foci formation in syndecan-1 deficient
animals (p=0.02). These data show that the effect of this particular
LMWH on secondary tumor formation is syndecan-1 independent
and suggest that the cancer inhibiting effect of LMWHs may not be
mediated by restoration of glycocalyx barrier function.
Some aspects of the experimental set-up require further
comments. First, a lower amount of cancer cells was injected in
the second experiment (Figure 2) in order to achieve lower numbers
of pulmonary tumor foci that could be assessed more easily.
Consequently, the wild type mice had less pulmonary tumor foci
than in Figure 1. Moreover, syndecan-1-deficient mice appeared to
be even better protected to secondary tumor formation than mice
which received a single dose of hyaluronidase (approximately 80%
versus 33% reduction in tumor foci in syndecan-1 deficient and
hyaluronidase treated mice, respectively). This may imply that long
term irreversible glycocalyx damage is more protective than
temporally enzyme-mediated glycocalyx damage.
In conclusion, our data show that targeted interference of either
hyaluronan or heparan sulfate limits experimental metastasis
suggesting that the net effect of the glycocalyx is pro-metastatic.
Moreover, the effect of enoxaparin on cancer progression and
cancer cell metastasis is glycocalyx independent.
Materials and Methods
Hyaluronidase and heparin
Bovine testicular hyaluronidase (type IV-S; Sigma-Aldrich, St.
Louis, MO) dissolved in 0.9% NaCl was administered intrave-
nously in a dose of 100 units per mouse 1h prior to cancer cell
inoculation [4]. LMWH (15 mg/kg; enoxaparin, Sanofi-Aventis,
Paris, France) was injected 30 min prior to and 6, 12 and 24 h
after cancer cell inoculation.
Cells and cell culture
Murine B16F10 melanoma cells were obtained from the
American Type Culture Collection (ATCC; Manassas, VA). Cells
were cultured in Dulbecco Modified Eagle Medium (DMEM;
Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum
(Sigma-Aldrich), 1% penicillin-streptomycin solution and 1% L-
glutamine at 37uC as described before [29,30]. Single cell
suspensions were prepared from 2 mM EDTA-treated monolay-
er’s which were washed and diluted in phosphate-buffered saline
(PBS) prior to counting and inoculation. Cells were stored on ice
until administration.
Animals
Eight to ten week-old C57Bl/6 male mice (Charles River,
Maastricht, The Netherlands) were maintained at the animal care
facility of the Academic Medical Centre, Amsterdam, The
Netherlands according to institutional guidelines. Syndecan-1
2/2 male mice on a C57Bl/6 background were housed and bred
in the Radboud University Nijmegen Medical Centre and handled
as described [31–34]. Animal procedures were carried out in
compliance with Institutional Standards for Humane Care and
Use of Laboratory Animals. The institutional Animal Care and
Use Committee approved all experiments (protocol number
DIX101092).
Experimental pulmonary metastasis model
Cancer cells (suspended in 200 ml PBS) were injected into the
lateral tail vein as described before [35–37]. In the first experiment,
3.5610
5 cancer cells were administered per mouse, whereas in the
second experiment 2.0610
5 cells were used in order to lower the
amount of secondary tumor foci for purpose of countability. After
14 days, mice were sacrificed and lungs were prepared as described
before [30]. Secondary tumor formation on the surface of the lungs
wascountedmacroscopicallyina blinded fashionwithrespect tothe
intervention. Experiments were performed with 8 mice per group.
Statistical analysis
Statistical analysis was carried out in GraphPad Prism version
4.03. Data are expressed as means +/2 SEM or medians with
interquartile range. For normally distributed data, significance was
assessed with the Student t-test. For not normally distributed data,
non-parametrictesting was performedusing the Mann-Whitneytest.
Statistical significance was assumed when the p-value was ,0.05.
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Figure 2. Pulmonary tumor foci formation in syndencan-1 2/2
versus wild type mice with and without treatment with LMWH.
Syndecan-1 2/2 and wild type mice were administered 2.0610
5 B16F10
melanoma cells into the lateral tail vein. One group of mice was treated
with LMWH (15 mg/kgenoxaparin ) priorto the administration of B16F10
melanoma cells and LMWH treatment was repeated after 6, 12 and 24 h.
Micewere sacrificed 14 days after cancer cell injectionandthe numberof
tumor foci at the surface of the lungs was determined. Error bars
represent medians 6 interquartile range (n=8), * p,0.05; *** p,0.001.
doi:10.1371/journal.pone.0011200.g002
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